Synthetic lethality in cancer therapy involves targeting gene interactions that are lethal only when both genes are dysfunctional, providing a promising avenue for personalized and precise treatments. Tumor cells often acquire mutations in DNA repair pathways, leading to resistance to traditional therapies. By identifying synthetically lethal gene pairs, researchers aim to selectively target cancer cells while sparing normal tissues. This review delves into the exploration of druggable synthetically lethal gene pairs for targeted cancer therapy, which have been uncovered through genetic screens and functional studies.
The genetic landscape of cancer is characterized by genomic instability, driven by aberrations in DNA maintenance mechanisms. Defects in genes involved in DNA damage recognition and repair pathways contribute to the uncontrolled growth of cancer cells. To counter these vulnerabilities, researchers are increasingly focusing on exploiting synthetic lethality, where the loss of function of one gene is survivable, but the simultaneous loss of two genes leads to cell death. Through systematic literature searches encompassing data from PubMed, Web of Science, Embase, and Scopus, this review aims to compile and analyze synthetically lethal gene pairs with potential therapeutic implications in cancer treatment.
Recent advancements in biotechnology have enabled the identification of novel synthetic lethal interactions through techniques like CRISPR screens. These screens have unveiled key gene pairs such as TSC2-STK11, KDM5C-BAP1, and SMARCA4/ARID1A-PTEN, shedding light on promising targets for anticancer therapies. Notably, PARP inhibitors have emerged as a successful example of targeting synthetic lethality, particularly in cancers with BRCA1/2 mutations. The concept of synthetic lethality holds immense promise in developing precision medicines that selectively eradicate cancer cells while minimizing off-target effects on healthy tissues.
The scoping review outlined in this study seeks to summarize and explore druggable synthetically lethal gene pairs that could serve as potential targets in precision cancer therapy. By leveraging the vulnerabilities arising from DNA repair pathway defects in cancer cells, targeted interventions can exploit synthetic lethality to enhance treatment efficacy. The review also underscores the importance of identifying and targeting synthetic lethal interactions to pave the way for novel cancer therapies with reduced side effects compared to conventional treatments.
In conclusion, the exploration of synthetic lethality in cancer treatment represents a paradigm shift towards more targeted and effective therapies. By deciphering the intricate gene interactions that underlie cancer cell survival, researchers are unraveling new possibilities for personalized medicine in oncology. As this field continues to evolve, the identification and validation of synthetically lethal gene pairs hold the key to unlocking innovative and tailored approaches for combating cancer.
- Targeting synthetic lethality in cancer therapy offers a promising strategy for precision medicine.
- Exploiting vulnerabilities in DNA repair pathways through synthetic lethality can enhance treatment efficacy.
- PARP inhibitors exemplify successful targeting of synthetic lethal interactions in cancers with specific mutations.
- The identification and utilization of synthetically lethal gene pairs hold significant potential for advancing precision cancer therapies.
Tags: clinical trials
Read more on pmc.ncbi.nlm.nih.gov